Exact Sciences Corp., expects to submit its application for a noninvasive, DNA-based test for detecting colon cancer to the Food and Drug Administration in May, said Kevin T. Conroy, president and chief executive officer. The company is ramping up its manufacturing capabilities, “laying the foundation” for insurance coverage of the test, and working to develop the market for it, he added. Read the full Milwaukee Journal Sentinel story here.